Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

Mutation loss in developed CT26 tumors after GAd CD8#5 and CD8#23 vaccine. A) Mice were immunized with mono-epitope GAd CD8#5 or B) CD8#23 vaccines and 14 days later, mice were inoculated s.c. with 2x10^5 CT26 cells. Mutation relative to nAg#5 (A) and nAg#23 (B) was checked by DNA sequencing in developed tumors. C) Table shows the percentage of mutation loss relative to nAg#5 (33%, E2f8 gene) and nAg#23 (0%, Mtch1 gene) in CT26 developing tumors after immunization with CD8#5 or CD8#23 vaccine.